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Background: Nicotinamide phosphoribosyl transferase (Nampt) plays a crucial role in tumorigenesis. The present
study examines whether genetic polymorphisms of NAMPT are related to the risk of developing esophageal
squamous cell carcinoma (ESCC).
Methods: A total of 810 subjects were enrolled in this study, including 405 ESCC patients and 405 healthy controls.
Using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), genotypes at rs61330082,
rs2505568 and rs9034 of NAMPT were identified. Haplotypes were constructed using PHASE software. Multivariate
logistic regression models were used to evaluate the potentiating effects of the genotypes, alleles and haplotypes
on the development of ESCC.
Results: The presence of genotypes CT and TT and allele T at rs61330082 was less frequent in ESCC cases than in
controls (48.89% vs. 53.33%, P < 0.01, 95% CI: 0.33-0.68; 18.52% vs. 30.37%, P < 0.01, 95% CI: 0.22-0.50; 42.96% vs.
57.04%, P < 0.01, 95% CI: 0.38-0.61; respectively). No statistically significant differences existed in the distributions of
genotypes or alleles at rs2505568 or rs9034 between ESCC cases and controls. Of five haplotypes constructed,
haplotypes CTC, CTT and CAC were higher in ESCC cases (P < 0.01, OR = 1.57, 95% CI: 1.16-2.12; P = 0.04, OR = 1.72,
95% CI: 1.03-2.85; P < 0.01, OR = 3.39, 95% CI: 1.99-5.75; respectively) than in controls.
Conclusion: Genetic polymorphisms of NAMPT, specifically genotype CC and allele C at rs61330082 as well as
haplotypes CTC, CTT and CAC, were significantly correlated with ESCC susceptibility.
Keywords: Nicotinamide phosphoribosyl transferase, Polymorphism, Haplotype, Esophageal squamous cell
carcinoma, SusceptibilityBackground
Esophageal cancer is relatively common throughout the
world. In 2008, approximately 482,300 new esophageal can-
cer cases were diagnosed and 406,800 deaths occurred [1].
Notably, almost 90% of cancer cases in the so-called
“Esophageal Cancer Belt,” a region stretching from north-
ern Iran through the Central Asian Republics to north-
central China, are diagnosed as esophageal squamous cell
carcinoma (ESCC). Common risk factors for ESCC include
poor nutrition, a lack of adequate vitamin intake, tobacco* Correspondence: chenziping1966@163.com
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unless otherwise stated.smoking, excessive alcohol consumption, Barrett's Esopha-
gus and mold pollution, among others [2]. In recent years,
hereditary factors have also gained increasing attention for
their role in the development of ESCC.
Nicotinamide phosphoribosyl transferase (Nampt) was
first identified as pre-B-cell colony enhancing factor (PBEF).
The NAMPT gene is located on chromosome7q22, spans
34.7 kb, has 11 exons and 10 introns, and produces cDNA
of 2,357 kb translated into a 491-amino acid, 52-kDa pro-
tein that stimulates early B-cell formation [3]. Nampt was
recently renamed “visfatin”, as it is a visceral, fat-derived
adipokine that might mimic insulin function [4], and it may
exist both intracellularly (iNampt) and extracellularly
(eNampt). Nampt is also known to act as a rate-limitingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cause NAD availability is crucial for many vital cellular
processes, including transcription regulation, DNA re-
pair, cell cycle progression, apoptosis, calcium homeo-
stasis, telomerase activity, antioxidation and oxidative
stress, energy metabolism, circadian rhythm maintenance
and chromatin dynamics regulation, and regulates factors
of genomic stability and organismal metabolic homeosta-
sis, including histone deacetylases (SirT1-T7), COOH-
terminal binding proteins, CD38, poly(ADP-ribose) and
polymerases [5,6]. Additionally, iNampt is involved in
angiogenesis by activating the extracellular signal regu-
lated kinase (ERK) 1/2 pathway and promoting the pro-
duction of vascular endothelial growth factor (VEGF) and
matrix metalloproteinase (MMP) 2/9 [7]. Independent of
its enzymatic activity, eNampt plays a major role as a cyto-
kine in the regulation of immune response [8]. Nampt is
one of a few emerging adipokines (eg. leptin, adiponectin)
whose expressions are correlated with the development of
a variety of cancers [9]. Furthermore, a series of studies
showed that Nampt might be a good biomarker of malig-
nant potential and stage progression [8,10,11].
NAMPT shows a high degree of evolutionary conserva-
tion, suggesting that only tiny genetic changes can pro-
foundly affect protein function and its dependent events.
To date, the relationship between NAMPT genetic poly-
morphisms and disease has only been examined in bladder
cancer, obesity and acute lung injury [12-14]. The aim of
this study was to be the first to explore the relationship
between NAMPT genetic polymorphisms and susceptibil-
ity to ESCC. Therefore, this case–control study was con-
ducted using subjects recruited in Anyang, China, an area
of high ESCC incidence. Three SNPs of NAMPT, includ-
ing rs61330082 in the promoter region and rs2505568 and
rs9034 in the 3’untranslated region (3’ UTR), were se-
lected for this study because of their potential effects on
the influence of Nampt expression.
Methods
Study subjects
A total of 405 ESCC patients were recruited from Anyang
Tumor Hospital in Henan Province from February 2005
to July 2011. These subjects were diagnosed as having
ESCC by qualified pathologists using endoscopic biopsies
or surgical specimens, had no history of any other cancer
and had not previously received chemotherapy or radio-
therapy. The control group consisted of 405 gender- and
age-matched (±1 year), healthy and genetically unrelated
individuals recruited during the same time period from
the same region. Each subject was required to sign an
informed consent and complete a personal questionnaire,
which included fields for demographic data and the related
risk factors age, gender, tobacco smoking and alcohol con-
sumption, prior to being included in this study. The ethicapproval was provided by the ethic committee of Shandong
Provincial Qianfoshan Hospital, Shandong University.
DNA extraction
A 5-ml blood sample was collected from each subject,
then genomic DNA was extracted using the Qiagen DNA
Isolation Kit (Qiagen, Dusseldorf, Germany).
Genotyping
Genotypes at rs61330082, rs2505568 and rs9034 of NAMPT
were identified by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP). Sequen-
cing primers for rs61330082 and rs2505568 were used
as previously described [12], and primers for rs9034
were designed using PRIMER 5.0 software (Canada). In-
formation on primer sequences, the sizes of PCR prod-
ucts, restriction enzymes, enzyme digestion temperatures
and restriction products is shown in Additional file 1:
Table S1. PCR amplification was performed in a 20-μl re-
action mixture containing 50–100 ng genomic DNA,
0.4 μl dNTPs (10 mM, Promega, USA), 0.8 μl each primer
(10 mM, SinoGenoMax Co., Ltd.), 0.5 U Hotstart Taq
DNA polymerase (5 U/μL, Qiagen, Dusseldorf, Germany)
and 2 μl 10× PCR buffer. The PCR mixture was incubated
for 2 min initial denaturation at 94.0°C followed by 36 cy-
cles of 30 s denaturation at 94.0°C, 50 s annealing at the
respective annealing temperatures (61°C, 52°C and 61°C,
respectively) and 1 min extension at 72.0°C. The final ex-
tension was carried out for 10 min at 72.0°C. The PCR
products were digested overnight by restriction enzymes
at 37.0°C, then the digested products were analyzed fol-
lowing electrophoresis on a 3% agarose gel and photo-
graphing under UV light. To confirm the existence of
polymorphisms, 10% of PCR products were directly se-
quenced. The representative pictures about the PCR-RFLP
results and sequencing analysis were added in Additional
file 2: Figure S1.
Statistical analysis
Distribution of age between the cases and controls was
compared using the Mann–Whitney U test, differences
between the other demographic variables were compared
using the McNemar test, and the observed genotype fre-
quencies were tested for Hardy-Weinberg equilibrium
using the chi-square test. PHASE 2.1 software (University
of Chicago, USA) was used to construct haplotypes on the
basis of the known genotypes and estimate haplotype fre-
quencies. The possible effects of the genotypes, alleles and
haplotypes on ESCC susceptibility were analyzed by odds
ratio (OR) and 95% confidence interval (95% CI) using
multivariate logistic regression models adjusted for age,
gender, tobacco smoking and alcohol consumption. All
tests were two-sided, and P values of < 0.05 were consid-
ered statistically significant. All statistical analyses were






Pa ORa (95% CI)
n % n %
rs61330082
CC 132 32.59 66 16.30 1.00 1.00
CT 198 48.89 216 53.33 <0.01 0.47 (0.33-0.68)
TT 75 18.52 123 30.37 <0.01 0.33 (0.22-0.50)
C Allele 462 57.04 348 42.96 1.00 1.00
T Allele 348 42.96 462 57.04 <0.01 0.48 (0.38-0.61)
rs2505568
TT 168 41.48 171 42.22 1.00 1.00
AT 237 58.82 234 57.78 0.91 1.02 (0.77-1.34)
AA 0 0.00 0 0.00 - -
T Allele 573 70.74 576 71.11 1.00 1.00
A Allele 237 29.26 234 28.89 0.92 1.02 (0.77-1.34)
rs9034
TT 0 0.00 0 0.00 - -
CT 51 12.59 36 8.89 1.00 1.00
CC 354 87.41 369 91.11 0.09 0.64 (0.38-1.07)
T Allele 51 6.30 36 4.44 1.00 1.00
C Allele 759 93.70 774 95.56 0.13 0.70 (0.45-1.10)
aConditional logistic regression adjusted for risk factors (tobacco smoking,
alcohol consumption).
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Results
Demographic information of the subjects
The potential influence of age, gender, tobacco smoking
and alcohol consumption on ESCC susceptibility was con-
sidered. As summarized in Table 1, the results showed that
there were no significant differences in age or gender be-
tween groups or in the distributions of gender, tobacco
smoking and alcohol consumption.
Correlation of NAMPT genotypes and alleles with ESCC
susceptibility
All genotypes at the three NAMPT SNPs of the cases and
controls were identified, and their distributions were
found to be in Hardy-Weinberg equilibrium (P > 0.05).
Table 2 shows that a significantly smaller proportion of
the cases possessed either genotype CT or TT at
rs61330082 than the controls (48.89% vs. 53.33%, P < 0.01;
18.52% vs. 30.37%, P < 0.01; respectively). Analogously, the
frequency of allele T at rs61330082 in the cases was signifi-
cantly decreased compared with the controls (42.96% vs.
57.04%, P < 0.01). Thus, subjects with genotypes CT or
TT or allele Tat rs61330082 were less susceptible to ESCC
(OR = 0.47, 95% CI: 0.33-0.68; OR = 0.33, 95% CI: 0.22-
0.50; OR = 0.48, 95% CI: 0.38-0.61; respectively). Notably,
no subjects carried genotype AA at rs2505568 or genotype
TT at rs9034. With respect to the distributions at the two
sites, no significant differences were found between the
cases and controls (P > 0.05).
Correlation of NAMPT haplotypes with ESCC susceptibility
Five haplotypes were constructed using PHASE software.
As summarized in Table 3, the presence of haplotypes a
(TTC) and b (TAC) was less frequent in the cases thanTable 1 Demographic information of the subjects
Characteristics Cases (n = 405) Controls (n = 405) P
n % n %
Age (year; mean ± SD) 60.89 ± 7.83 60.93 ± 7.91 0.87a
Gender
Male 240 59.26 240 59.26 -
Female 165 40.74 165 40.74
Tobacco smoking
Ever 183 45.19 171 42.22 0.43b
Never 222 54.81 234 57.78
Alcohol consumption
Ever 117 28.89 96 23.70 0.11b
Never 288 71.11 309 76.30
aMann–Whitney U test.
bMcNemar test.in the controls (29.39% vs. 36.26%; 13.21% vs. 19.47%; re-
spectively). Conversely, the presence of haplotypes CTC,
CTT and CAC was more frequent in the cases than in the
controls (36.17% vs. 30.91%; 4.81% vs. 2.94%; 14.92% vs.
8.92%; respectively). Each haplotype was then assessed for
its ability to estimate susceptibility to ESCC (Table 4). Car-
riers with haplotypes TTC (−/a + a/a) or TAC (−/b + b/b)
were less susceptible to ESCC (P < 0.01, OR = 0.61, 95%
CI: 0.46-0.79; P < 0.01, OR = 0.69, 95% CI: 0.52-0.90; re-
spectively) than those without these haplotypes (−/−).
Conversely, individuals with haplotypes CTC, CTT or
CAC (−/c + c/c, −/d + d/d or -e/e + e/e) were moreTable 3 Distributions of the estimated haplotype
frequencies




rs6133082 rs2505568 rs9034 n %a n %a
a T T C 238 29.39 294 36.26
b T A C 107 13.21 158 19.47
c C T C 293 36.17 250 30.91
d C T T 39 4.81 24 2.94
e C A C 121 14.92 72 8.92
aConditional calculated by PHASE software.






Pa ORa (95% CI)
n % n %
a = TTC
−/−b 258 63.70 204 50.37 1.00 1.00
-/a + a/a 147 36.30 201 49.63 <0.01 0.61 (0.46-0.79)
b = TAC
−/− 237 58.52 195 48.15 1.00 1.00
-/b + b/b 168 41.48 210 51.85 <0.01 0.69 (0.52-0.90)
c = CTC
−/− 111 27.41 147 36.30 1.00 1.00
-/c + c/c 294 72.59 258 63.70 <0.01 1.57 (1.16-2.12)
d = CTT
−/− 354 87.41 372 91.85 1.00 1.00
-/d + d/d 51 12.59 33 8.15 0.04 1.72 (1.03-2.85)
e = CAC
−/− 336 82.96 381 94.07 1.00 1.00
-/e + e/e 69 17.04 24 5.93 <0.01 3.39 (1.99-5.75)
aLogistic regression model, adjusted for age, gender, tobacco smoking and
alcohol consumption.
bThe minus sign (−) denotes any haplotype. For example: −/a indicates the a
haplotype in combination with any other haplotype.
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2.12; P = 0.04, OR = 1.72, 95% CI:1.03-2.85; P < 0.01,
OR = 3.39, 95% CI:1.99-5.75; respectively) than those
without these haplotypes (−/−).Discussion
Esophageal cancer has a poor prognosis, and in 2009, its
mortality ranked the fourth and its incidence fifth
among all reported cancers in China [2]. While esopha-
geal cancer has been studied in depth, the specific mech-
anism by which it develops is still unclear. Given the
known influence of genetic polymorphisms on certain
types of cancer, it was important for this group to
analyze the as yet unknown association between genetic
polymorphisms and ESCC susceptibility, particularly
since we are located within a high-ESCC-incidence re-
gion of China. For this study, NAMPT was selected as a
basis for analyzing this association.
The adipokine Nampt was first reported as a pleio-
tropic protein, and is widely known as a key regulator of
NAD, which is intimately involved in proliferation, cyto-
kine production, immunological regulation and angio-
genesis. Nampt is overexpressed in a variety of cancers,
including that of the stomach and colorectal cavity
[15,16], and its inhibitor FK866 is a widely studied anti-
cancer agent [17].In this study, the results demonstrated that the presence
of genotypes CT and TT and allele T at rs61330082 of
NAMPT was significantly decreased in the cases compared
with the controls. It was therefore suggested that these ge-
notypes or this allele might reduce ESCC susceptibility. In
other words, genotype CC or allele C at rs61330082 might
increase carrier susceptibility to ESCC. Considering the
rs61330082 loci in the promoter region, its genetic muta-
tion might influence the structure or function of Nampt
protein. This finding is therefore commensurate with the
probable roles of NAMPT in tumorigenesis and its elevated
expression in gastric and colorectal cancers [15,16]. Al-
though its expression did not vary in ESCC [18] and its
genetic polymorphisms were never studied in ESCC, this
result was consistent with a similar bladder cancer study by
Zhang et al. [12].
Genotype AA at rs2505568 and genotype TT at rs9034
could not be detected in this study, which was a similar
finding to Zhang’s previous study [12]. Whether the lim-
ited sample size in that study was responsible for the ab-
sence of these genotypes in bladder cancer deserves
further research. In spite of the importance of the 3’
UTR on the regulation of gene expression, polymor-
phisms at rs2505568 and rs9034 were found to be inde-
pendent risk factors for the development of ESCC, also
partially coinciding with Zhang’s study [12], although
pathogenesis between ESCC and bladder cancer is com-
paratively limited.
Haplotype analysis assessed disease susceptibility more
powerfully by analyzing the combined action of multiple
loci. From the selected genetic sites, five haplotypes were
constructed. The presence of haplotypes CTC, CTT or
CAC was positively correlated with the development of
ESCC, while the presence of haplotypes TTC or TAC
protected carriers from ESCC. The determinant impact
of allele C at rs61330082 among the three SNPs is thus
implied.
This study had certain limitations worth noting. Specif-
ically, the findings need to be confirmed by a larger sam-
ple of the population from more high-ESCC-incidence
regions, and there are many more convenient and effective
methods of confirming genotypes than PCR-PFLP.
Additionally, functional studies and gene-environment
interaction studies are needed to offer more authentic
and integrative proof about the influence of NAMPT
on ESCC.Conclusions
In summary, genetic polymorphisms of NAMPT were
significantly correlated with ESCC susceptibility in the
studied Chinese population. Genotype CC and allele C
at rs61330082 as well as haplotypes CTC, CTT and
CAC were each risk factors for ESCC. Thus, these
Zhang et al. BMC Gastroenterology  (2015) 15:49 Page 5 of 5findings might provide one or more novel diagnostic
indicators for ESCC.
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